Portfolio Composition at the end of October 2014



Here is a new edition of my portfolio composition. The last two months have not been particularly kind to my portfolio performance, as can be seen in the next post. In fact, partly due to the fact that I was travelling, and partly due to procrastination due to my relative poor performance in September, I missed putting up my portfolio at the end of September.

But here I am, with my portfolio at the end of October 2014. As usual, this is not a complete disclosure of my portfolio. This list is only of those scripts which constitute more than 1% of my portfolio. Nevertheless, I am also disclosing in the text below if there were major changes in the rest of the portfolio.

Stock Latest Price Inv. Price Overall Gain % Portfolio %
IDFC (97) 148.25 133.3108609 11.21 10.55%
Oberoi Realty (64) 242.15 238.5116518 1.53 8.96%
eClerx Services (18) 1,347.80 1029.558952 30.91 2.82%
ILandFS (36) 20.2 15.32131761 31.84 2.39%
Larsen (22) 1,597.70 1096.596358 45.7 2.13%
Cummins (4) 720.05 411.2417355 75.09 2.12%
MPS (14) 712.4 128.6641026 453.69 2.12%
Indian Hotels (20) 104.8 73.70118644 42.2 1.88%
Selan Explore (28) 487.9 317.7249493 53.56 1.83%
IRB Infra (18) 254.5 90.26702128 181.94 1.82%
NMDC (28) 168.3 133.9162406 25.68 1.71%
Mayur Uniquoter (11) 430 111.0322327 287.27 1.67%
Balkrishna Ind (11) 756.3 232.4213927 225.4 1.61%
Kaveri Seed (13) 915.45 296.6391304 208.61 1.60%
HPCL (13) 522.15 470.71725 10.93 1.59%
Bharat Forge (9) 801.4 272.25 194.36 1.59%
Shilpa (11) 539.65 370.2180563 45.77 1.49%
Munjal Auto Ind (11) 117.45 33.99787765 245.46 1.43%
PTC India Fin (6) 50.1 14.68682894 241.12 1.36%
Oriental Carbon (9) 382.6 113.2114733 237.95 1.34%
Muthoot Cap (11) 253.2 97.38 160.01 1.33%
Ajanta Pharma (14) 1,887.60 1007.725543 87.31 1.32%
Sesa Sterlite (3) 253.05 150.9941003 67.59 1.31%
Sun Pharma Adv (19) 196.5 123.5597701 59.03 1.30%
EID Parry (13) 218.85 141.47 54.7 1.30%
Poly Medicure (7) 833.15 280.2228601 197.32 1.22%
PI Industries (11) 429.9 171.8891892 150.1 1.21%
Hind Zinc (18) 168.95 121.9935484 38.49 1.20%
RS Software (11) 630.9 204.2701613 208.86 1.19%
Grindwell Norto (7) 526.05 256.5177241 105.07 1.16%
TCS (9) 2,558.20 1953.9 30.93 1.13%
Reliance (7) 979.25 810.3029891 20.85 1.10%
Sobha Developer (14) 430.9 314.4363636 37.04 1.08%
Akzo Nobel (5) 1,299.05 1027.196154 26.47 1.03%
Tata Inv Corp (13) 556.5 404.9865 37.41 1.02%
ICICI Bank (9) 1,614.05 948.6365854 70.14 1.01%

The movement towards consolidation continues. However, this is also tempered by the fact that I have bought new scripts in the last two months. Nevertheless, the number of scripts which have at least a 1% contribution to my portfolio is 37 (compared with 33 at the beginning of September 2014), and together they constiture 71% of my portfolio. As before 32% of the portfolio was invested in the top 8 scripts.

What have I been buying in the last two months? And what did I sell?

Well, I continued to purchase IDFC, Oberoi Realty and IL&FS Investment Managers, averaging down as the stocks fell all of September, and most of October. It requires great guts or folly to keep buying in the face of negative outcomes from a stock price point of view, and sometime in November, I hope to have a post which will talk about these dilemnas.

I also purchased a significant quantity of L&T and TCS, again as they fell. In addition, I added a small quantity of Jaypee Infra, Sobha Developers and DLF, when they fell rather sharply because of a weak real estate environment and negative news flow.

In general, I have also resolved to improve the quality of my portfolio, from a cap goods, finance and realty bias to more quality names with better moats. To this end, I made significant purchases of Indian Hotels (Convertible Debentures) Akzo Nobel (which now is in the list of 1% stocks), United Spirits (which is almost there), and Dr Reddy’s Labs.

In terms of my older themes, I bought significant quantities of Reliance, Bayer CropScience, India Bulls Housing Finance, Gujarat Pipapav Port, and Vardhman Testiles.

What did I sell? Only RS Software at a time when the stock really shot up. At that price of 730 or so, the stock is more expensive than say EClerx, and EClerx has a superior track record of governance, disclosure, earnings, and dividends. I still own significant RS Software, and given my purchase price, I will evaluate my position only after a quarter or two.

Leave a Reply

Your email address will not be published. Required fields are marked *